• IPR-803: Transforming Tumor Microenvironment in Cancer Resea

  2026-06-12

  Explore how IPR-803, a leading urokinase receptor inhibitor, enables advanced strategies to remodel the tumor stroma and enhance drug delivery in breast and pancreatic cancer research. This in-depth article reveals unique translational applications and protocol guidance you won’t find elsewhere.

• Calnexin’s Role in CFTR Variant Rescue and Corrector Sensiti

  2026-06-12

  Tedman et al. systematically dissect the impact of the ER chaperone calnexin on the expression and pharmacological rescue of over 200 clinical CFTR variants. Their findings reveal that calnexin is pivotal for both efficient CFTR protein trafficking and the efficacy of small-molecule correctors, with implications for variant-specific and personalized approaches in cystic fibrosis research.

• GOT1 Inhibition Reprograms Glutamine Metabolism in Pancreati

  2026-06-11

  A recent study demonstrates that ziprasidone, a known antipsychotic, inhibits GOT1 and disrupts glutamine metabolism in pancreatic ductal adenocarcinoma (PDAC) cells. This metabolic intervention impairs tumor proliferation by destabilizing redox homeostasis, revealing new therapeutic avenues for targeting metabolic vulnerabilities in PDAC.

• DAPT (GSI-IX): Unlocking γ-Secretase Control in Disease Mode

  2026-06-11

  DAPT (GSI-IX) empowers precise modulation of Notch and amyloid precursor protein signaling, enabling robust disease modeling across neuroscience, oncology, and immunology. This guide details experimental workflows, advanced troubleshooting, and key insights from recent sensory neuron research for optimized γ-secretase inhibition.

• PF-562271 HCl: Selective FAK/Pyk2 Inhibitor for Cancer Resea

  2026-06-10

  PF-562271 HCl is a potent, ATP-competitive inhibitor of focal adhesion kinase (FAK) and Pyk2, offering high selectivity and nanomolar potency. This compound demonstrates robust tumor growth inhibition through suppression of FAK phosphorylation, supporting its application in cancer research and therapeutic development.

• ERAD-Engaging Chimeras: A Platform for Targeted TM Protein D

  2026-06-10

  Song et al. (2026) introduce ERAD-engaging chimeras (ERADECs), a novel small-molecule strategy that harnesses the ER-associated degradation (ERAD) pathway for selective elimination of transmembrane proteins. This approach overcomes limitations of current targeted protein degradation methods and holds promise for advancing research in membrane protein modulation and disease intervention.

• Palonosetron in CINV Prevention: Insights for Colorectal Can

  2026-06-09

  Ruhlmann and Herrstedt's review highlights the unique pharmacology and clinical performance of palonosetron hydrochloride in preventing chemotherapy-induced nausea and vomiting (CINV), with a focus on its advantages over earlier 5-HT3 receptor antagonists. Their analysis, based on preclinical and clinical studies, informs protocol optimization for oncology researchers working with chemotherapeutics such as irinotecan.

• Tunicamycin: Gold-Standard N-Glycosylation Inhibitor for ER

  2026-06-09

  Tunicamycin is a potent, crystalline N-glycosylation inhibitor widely used to induce endoplasmic reticulum (ER) stress and study inflammation suppression in macrophages. Its mode of action, evidence base, and practical integration for research are well-established. Studies confirm its unique ability to disrupt glycoprotein synthesis and trigger the unfolded protein response under tightly controlled conditions.

• GI 254023X: ADAM10 Inhibitor for Vascular and Apoptosis Rese

  2026-06-08

  GI 254023X offers precise, nanomolar potency for selective ADAM10 inhibition, enabling researchers to dissect cell signaling, apoptosis, and endothelial barrier integrity. Its robust selectivity profile and proven workflow enhancements set a new benchmark for both vascular and neurodegeneration studies.

• VX-661 F508del CFTR Corrector: Protocols, Workflows & Pitfal

  2026-06-08

  VX-661 (F508del CFTR corrector) empowers researchers to restore mutant CFTR trafficking and function in cystic fibrosis models, with unique strengths in calnexin-dependent variant rescue. This article delivers optimized experimental workflows, advanced troubleshooting, and practical insights from recent proteostasis research—enabling more reproducible, translationally relevant cystic fibrosis studies.

• Macrophage EP4 Deficiency Accelerates Atherosclerosis via CD

  2026-06-07

  This study reveals that the loss of the EP4 receptor in macrophages intensifies atherosclerosis progression by enhancing CD36-mediated lipid uptake and promoting M1 macrophage polarization. These findings clarify a previously ambiguous mechanism in atherogenesis and provide a molecular basis for future targeted therapies.

• α-Linolenic Acid in Lipid Metabolism and Immunometabolic Res

  2026-06-06

  Harness the full experimental power of α-Linolenic Acid (ALA) for probing lipid metabolism, cardiovascular function, and immunometabolic signaling. This guide details applied workflows, troubleshooting strategies, and innovations that optimize ALA-driven research using APExBIO's high-purity reagent.

• BKT140 (BL-8040): Strategic CXCR4 Antagonism in Oncology Res

  2026-06-05

  This thought-leadership article synthesizes mechanistic insights and strategic guidance for translational researchers exploring CXCR4 antagonism in cancer. It contextualizes BKT140 (BL-8040) as a pivotal tool for dissecting tumor microenvironment interactions, stem cell mobilization, and precision oncology workflows. Integrating recent theranostic advances in lymphoma and solid tumors, the discussion bridges molecular rationale, experimental protocols, clinical translation, and future horizons—escalating the dialogue beyond standard product pages and actionable guides.

• Phalloidin (B7678): Technical Guide for F-Actin Stabilizatio

  2026-06-05

  Phalloidin (SKU B7678) is a cyclic heptapeptide toxin used for high-affinity stabilization and visualization of F-actin in fixed or permeabilized samples. It is optimal for static analysis of actin cytoskeleton organization but is not suitable for live-cell imaging or studies requiring reversible actin binding.

• (-)-Arctigenin: New Leverage Against NF-κB Signaling in Brea

  2026-06-04

  This article explores how (-)-Arctigenin, a high-purity MEK1 inhibitor and iNOS expression inhibitor from APExBIO, empowers translational researchers to dissect and intervene in tumor microenvironment crosstalk—particularly focusing on the role of NF-κB activation via TAM-derived extracellular vesicles in metastatic breast cancer. Integrating mechanistic insight with protocol-level guidance, the discussion bridges the latest clinical findings, strategic workflow optimization, and a forward outlook on anti-inflammatory and antiviral research.

16323 records 1/1089 page Next 12345 下5页 Last page